Navigation Links
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Date:9/4/2007

evidence for the drug's activity as well as help inform dose selection for future studies."

ISIS 325568 Targets the Glucagon Receptor (GCGR)

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to improved glucose control and reduced levels of blood triglycerides without producing hypoglycemia. In addition, treatment with ISIS 325568 led to an increase in circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for diabetes and metabolic diseases, and the potential of the antise
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... Feb. 14, 2012 Glenveigh Medical  announced today that ... its request for orphan drug designation for a potential ... compound, digoxin immune fab (ovine) , is an ... toxicity. Glenveigh, a nationally renowned life science company, has ...
... 14, 2012 ZONARE Medical Systems, Inc., a developer ... of Timothy A. Marcotte to President and Chief Executive ... served as Chief Operating Officer with responsibility for the ... the company,s Chief Financial Officer.  Prior to ZONARE, he ...
Cached Medicine Technology:Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia 2ZONARE Medical Systems Announces Appointment of Timothy A. Marcotte as President and Chief Executive Officer 2
(Date:7/28/2014)... 28, 2014 Cape Regional Medical ... Exchange technology solution in an effort to ... support collaboration with their New Jersey health information ... center located in New Jersey, serves the local ... a variety of inpatient and outpatient services. With ...
(Date:7/28/2014)... News) --,The more chronic medical conditions people have at ... a new study claims. Since nearly four ... at Johns Hopkins Bloomberg School of Public Health in ... in life expectancy are slowing in the United States. ... kidney disease and heart failure is now the norm ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... have dementia and heart rhythm irregularities are more likely to ... found. In fact, the study of more than 16,000 ... percent more likely to get a pacemaker than those without ... study is why folks with dementia are so much more ...
(Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
(Date:7/28/2014)... JOLLAWhen you,re expecting somethinglike the meal you,ve ordered ... unique electrical rhythms sweep through your brain. ... they reflect a symphony of cellsboth excitatory and ... role has been debated, gamma waves have been ... the patterns have been tied to schizophrenia, Alzheimer,s ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... grant of Rs.190 million ($4.17 million) to prevent the ... agreement to this effect was signed by US Ambassador ... (WHO) representative to India Salim Habayeb. ,The ... India undertake research and implement the national disease control ...
... has given GlaxoSmithKline PLC's anti-seizure medicine to treat Primary ... ,According to GlaxoSmithKline, the U.K. pharmaceutical company, the drug, ... and older, as well as adults. ,PGTC ... occurring type of generalized seizures, seen in about 20% ...
... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
... most rural counties of the United States are hospitalized ... //by HHS Agency for Healthcare Research and Quality and ... Ambulatory Pediatrics. ,The study, which was led by ... of health care, health status, and other measures for ...
... anthrax attacks in the United States in 2001 had the ... the anthrax used//, belonged to the common variety, though lethal ... into the source of anthrax that reportedly killed five people ... 11 twin tower disaster. ,The Anthrax which claimed ...
... The Good Shepherd Medical Center in Oregon is providing healthy ... eating habits.// Foods from wild salmon to local organic foods ... a topping of antioxidant-rich dried cherries. , Angela ... Hermiston, OR for five days recently for the delivery of ...
Cached Medicine News:Health News:Local Health Care Limited for Rural Children 2
... The Gellhorn Pessary is used ... degree prolapse, or procidentia. It ... base and comes in nine ... Gellhorn easily folds over for ...
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... The BioArc™ System treats female urinary stress ... using either a suprapubic (BioArc™ SP) or ... is an innovative hybrid system combining synthetic ... hybrid sling currently available. The BioArc utilizes ...
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
Medicine Products: